Eqis Capital Management Inc. Raises Position in Eli Lilly and Company (LLY)

Eqis Capital Management Inc. raised its stake in Eli Lilly and Company (NYSE:LLY) by 32.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,574 shares of the company’s stock after buying an additional 2,570 shares during the period. Eqis Capital Management Inc.’s holdings in Eli Lilly and Company were worth $889,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. First Command Financial Services Inc. boosted its stake in shares of Eli Lilly and Company by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares during the period. LeJeune Puetz Investment Counsel LLC bought a new stake in Eli Lilly and Company during the fourth quarter valued at $136,000. Crestwood Advisors Group LLC bought a new stake in Eli Lilly and Company during the first quarter valued at $179,000. Alpha Windward LLC raised its stake in Eli Lilly and Company by 2.0% in the first quarter. Alpha Windward LLC now owns 2,251 shares of the company’s stock valued at $189,000 after buying an additional 44 shares during the last quarter. Finally, Moloney Securities Asset Management LLC bought a new stake in Eli Lilly and Company during the first quarter valued at $202,000. Institutional investors and hedge funds own 75.44% of the company’s stock.

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Shares of Eli Lilly and Company (NYSE:LLY) opened at 81.88 on Friday. The firm has a market capitalization of $86.49 billion, a price-to-earnings ratio of 39.59 and a beta of 0.36. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72. The stock has a 50 day moving average price of $80.08 and a 200-day moving average price of $78.91.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, April 25th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.96 by $0.02. Eli Lilly and Company had a return on equity of 26.64% and a net margin of 10.13%. The business had revenue of $5.23 billion for the quarter, compared to analyst estimates of $5.22 billion. During the same period in the previous year, the company earned $0.83 earnings per share. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. On average, analysts anticipate that Eli Lilly and Company will post $4.12 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, June 9th. Stockholders of record on Monday, May 15th were given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date was Thursday, May 11th. Eli Lilly and Company’s payout ratio is 100.48%.

COPYRIGHT VIOLATION WARNING: “Eqis Capital Management Inc. Raises Position in Eli Lilly and Company (LLY)” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://transcriptdaily.com/2017/06/17/eqis-capital-management-inc-has-889000-stake-in-eli-lilly-and-co-lly-updated.html.

A number of research firms have weighed in on LLY. Zacks Investment Research upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $96.00 target price on the stock in a research note on Wednesday, April 12th. Morgan Stanley lowered Eli Lilly and Company from an “overweight” rating to an “equal weight” rating and set a $82.00 target price on the stock. in a research note on Monday, April 17th. BMO Capital Markets downgraded Eli Lilly and Company from a “market perform” rating to an “underperform” rating and dropped their price target for the stock from $73.00 to $71.00 in a research report on Monday, April 17th. Cowen and Company increased their price target on Eli Lilly and Company from $85.00 to $95.00 and gave the stock an “outperform” rating in a research report on Monday, April 17th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $100.00 price target on shares of Eli Lilly and Company in a research report on Monday, April 17th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $87.59.

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 30th. The stock was sold at an average price of $84.67, for a total value of $17,780,700.00. Following the completion of the transaction, the insider now directly owns 124,690,804 shares in the company, valued at $10,557,570,374.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Melissa S. Barnes sold 1,900 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the transaction, the insider now owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The disclosure for this sale can be found here. Insiders sold 259,733 shares of company stock valued at $21,829,137 over the last quarter. Insiders own 0.20% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply